Web Desc
Cancer Vaccines: Targeting Cancer Genes for Immunotherapy
joint with Antibodies as Drugs
Organizer(s): A. Karolina Palucka, Hyam I. Levitsky and Laurence Zitvogel
Date: March 06 - 10, 2016
Location: Fairmont Chateau Whistler, Whistler, BC, Canada
Sponsored by Regeneron Pharmaceuticals, Inc.
Summary of Meeting:
The past decade has seen tremendous developments in novel cancer therapies, through targeting of tumor cell-intrinsic pathways whose activity is linked to genetic alterations, as well as the targeting of tumor cell-extrinsic factors such as growth factors. Remarkable clinical success of checkpoint inhibitors as well as adoptively transferred genetically engineered T cells further demonstrates the critical role of T cells in cancer control and rejection. However, many patients still do not respond to checkpoint inhibitor therapies, possibly due to the lack of T cell repertoire with specificity against cancer antigens. This creates the need for effective means of expanding the T cells in patients via immunization, i.e., cancer vaccines. Much progress has been made in recent years in this regard, and several phase III clinical trials testing various approaches to therapeutic vaccination are ongoing. The challenge for next-generation vaccines is to resolve the discrepancy between the immune and clinical efficacy measured by the rate of cancer rejection. The future immunotherapy of cancer lies in combination approaches targeting T cells as well as cancer genes to combat underlying inflammation. Spectacular progress has been made in these two parallel fields, i.e., cancer genomics and genetics, and tumor immunology. It is time now to link these fields to enable the linking of genetic alterations with the type of immune response. The meeting will therefore host cancer geneticists, cancer biologists, experts in cancer antigen presentation, tumor immunologists and vaccinologists. It will discuss the immunological basis for therapeutic cancer vaccines and how the current understanding of cancer genomics, antigen presentation and T cell biology might enable development of next-generation curative therapies for patients with cancer.
Scholarship Deadline: November 5 2015
Discounted Abstract Deadline: November 5 2015
Abstract Deadline: December 8 2015
Discounted Registration Deadline: January 7 2016
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Regeneron Pharmaceuticals, Inc.
We gratefully acknowledge additional support for this conference from:
Dove Medical Press Ltd
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Genentech, Inc.

Juno Therapeutics
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, March 06 | 4:00PM - 8:00PM
Arrival and Registration
Room: Macdonald Foyer


Sunday, March 06 | 6:00PM - 8:00PM
Welcome Mixer
Room: Macdonald Foyer
No registration fees are used to fund alcohol served at this function.

Monday, March 07 | 7:00AM - 8:00AM
Breakfast
Room: Frontenac


Monday, March 07 | 7:30AM - 8:00AM
Poster Setup
Room: Frontenac


Monday, March 07 | 8:00AM - 5:00PM
Poster Viewing
Room: Frontenac


Monday, March 07 | 8:00AM - 10:00AM
Welcome and Keynote Session
Room: Macdonald DEF

Speaker 1 of 3
* A. Karolina Palucka, The Jackson Laboratory for Genomic Medicine, USA

Monday, March 07 | 8:00AM - 10:00AM
Welcome and Keynote Session
Room: Macdonald DEF

Speaker 2 of 3
Ronald N. Germain, NIAID, National Institutes of Health, USA
Visualizing and Deconstructing Immune Responses in situ

Monday, March 07 | 8:00AM - 10:00AM
Welcome and Keynote Session
Room: Macdonald DEF

Speaker 3 of 3
Sebastian Amigorena, Institut Curie, France
Regulation of Antigen Cross Presentation and Anti Tumor Immune Responses

Monday, March 07 | 10:00AM - 10:20AM
Coffee Break
Room: Macdonald Foyer


Monday, March 07 | 10:20AM - 11:30AM
Antigens
Room: Macdonald DEF

Speaker 1 of 3
* A. Karolina Palucka, The Jackson Laboratory for Genomic Medicine, USA

Monday, March 07 | 10:20AM - 11:30AM
Antigens
Room: Macdonald DEF

Speaker 2 of 3
Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
Synergy of Therapeutic Vaccination against HPV16 Oncogenic Proteins and Standard Chemotherapeutics

Monday, March 07 | 10:20AM - 11:30AM
Antigens
Room: Macdonald DEF

Speaker 3 of 3
Victor H. Engelhard, University of Virginia, USA
Phosphopeptides Displayed by MHC Molecules as New-Generation Cancer Vaccine Targets

Monday, March 07 | 10:20AM - 11:45AM
Getting Antibodies to Where They Need to Go
This session is from Antibodies as Drugs
Room: Macdonald ABC
The session will cover some of the major underlying challenges facing the field of antibody based therapeutics.
Speaker 1 of 4
* Peter D. Senter, Seattle Genetics Inc., USA


Monday, March 07 | 10:20AM - 11:45AM
Getting Antibodies to Where They Need to Go
This session is from Antibodies as Drugs
Room: Macdonald ABC
The session will cover some of the major underlying challenges facing the field of antibody based therapeutics.
Speaker 2 of 4
James M. Olson, Fred Hutchinson Cancer Research Center, USA
Micro Needle Technologies for Intratumoral Drug Delivery and Combination Screening


Monday, March 07 | 10:20AM - 11:45AM
Getting Antibodies to Where They Need to Go
This session is from Antibodies as Drugs
Room: Macdonald ABC
The session will cover some of the major underlying challenges facing the field of antibody based therapeutics.
Speaker 3 of 4
Alison M. Betts, Pfizer, Inc., USA
PK/PD Modeling for Macromolecular Drug Delivery


Monday, March 07 | 10:20AM - 11:45AM
Getting Antibodies to Where They Need to Go
This session is from Antibodies as Drugs
Room: Macdonald ABC
The session will cover some of the major underlying challenges facing the field of antibody based therapeutics.
Speaker 4 of 4
Richard Tavaré, University of California, Los Angeles, USA
Short Talk: Noninvasive Detection of Tumor-Infiltrating Lymphocytes using Anti-CD8 Immuno-PET: Impact of Protein Dose


Monday, March 07 | 11:30AM - 12:30PM
Lunch
Room: Frontenac


Monday, March 07 | 12:00PM - 2:30PM
Poster Session 1
Room: Frontenac


Monday, March 07 | 2:30PM - 4:30PM
Workshop 1: Molecular Vaccines
Room: Macdonald DEF

Speaker 1 of 9
* Darrell J. Irvine, Massachusetts Institute of Technology, USA

Monday, March 07 | 2:30PM - 4:30PM
Workshop 1: Molecular Vaccines
Room: Macdonald DEF

Speaker 2 of 9
* Yvette van Kooyk, Vrije University Medical Center, Netherlands

Monday, March 07 | 2:30PM - 4:30PM
Workshop 1: Molecular Vaccines
Room: Macdonald DEF

Speaker 3 of 9
Tomasz Ahrends, Netherlands Cancer Institute, Netherlands
Combined CD27-Costimulation and PD-1-Inhibition Recapitulates CD4+ T-cell Help in Therapeutic Vaccination Against Cancer

Monday, March 07 | 2:30PM - 4:30PM
Workshop 1: Molecular Vaccines
Room: Macdonald DEF

Speaker 4 of 9
Suresh de Silva, Heat Biologics Inc., USA
Combination Immunotherapy: T-cell Costimulation (OX40L, TL1A, 4-1BBL and ICOSL) Secreted Locally by Gp96-Ig Vaccines, Elicits Robust Antigen-Specific, Memory T Cell Responses and Tumor Elimination

Monday, March 07 | 2:30PM - 4:30PM
Workshop 1: Molecular Vaccines
Room: Macdonald DEF

Speaker 5 of 9
Christa I. DeVette, University of Oklahoma Health Sciences Center, USA
Development of Tools to Evaluate Anti-tumor Immunity

Monday, March 07 | 2:30PM - 4:30PM
Workshop 1: Molecular Vaccines
Room: Macdonald DEF

Speaker 6 of 9
James Moon, University of Michigan, USA
Nanodisc-Based Peptide Vaccines for Personalized Cancer Immunotherapy

Monday, March 07 | 2:30PM - 4:30PM
Workshop 1: Molecular Vaccines
Room: Macdonald DEF

Speaker 7 of 9
Geoffrey Lynn, Avidea Technologies, USA
Self-Assembling Nanoparticles Codelivering Peptide Neoantigens and TLR-7/8 Agonists Enhance the Breadth and Potency of Anti-Tumor Immunity

Monday, March 07 | 2:30PM - 4:30PM
Workshop 1: Molecular Vaccines
Room: Macdonald DEF

Speaker 8 of 9
Naveen Mehta, Massachusetts Institute of Technology, USA
Utilizing Protein Carriers to Engineer Cancer Vaccines with Improved Potency

Monday, March 07 | 2:30PM - 4:30PM
Workshop 1: Molecular Vaccines
Room: Macdonald DEF

Speaker 9 of 9
Kristen Radford, University of Queensland, Australia
Targeting Antigen to Human CD141+ Dendritic Cells via CLEC9A in vitro and in vivo Confers Effective Cross-Presentation to CD8+ T Cells

Monday, March 07 | 2:30PM - 4:30PM
Workshop 1: Novel Constructs
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 1 of 7
* Dennis R. Benjamin, Seattle Genetics Inc., USA


Monday, March 07 | 2:30PM - 4:30PM
Workshop 1: Novel Constructs
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 2 of 7
Jonathan H. Davis, Invenra, USA
Synergy Generates Picomolar Potency and a High Resistance Barrier in Combinectin, a Novel Trispecific HIV-1 Entry Inhibitor with Clinical Promise


Monday, March 07 | 2:30PM - 4:30PM
Workshop 1: Novel Constructs
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 3 of 7
Eric Hatterer, NovImmune.SA, Switzerland
Characterizing the Preclinical Candidate, NI-1701, a CD47 Targeting Bispecific Antibody in Development for the Treatment of B Cell Lymphomas and Leukemias


Monday, March 07 | 2:30PM - 4:30PM
Workshop 1: Novel Constructs
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 4 of 7
Paul A. Moore, MacroGenics, USA
MGD009, a B7-H3 x CD3 Bispecific Dual-Affinity Re-Targeting (DART®) Molecule Directing T Cells to Solid Tumors


Monday, March 07 | 2:30PM - 4:30PM
Workshop 1: Novel Constructs
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 5 of 7
Marijn A. Gillissen, Aimm Therapeutics / AMC, Netherlands
Donor-Derived B Cells Produce Potent AML-Specific Antibodies that Recognize a Novel Tumor-Specific Antigen and Mediate Graft-Versus- Leukemia Immunity


Monday, March 07 | 2:30PM - 4:30PM
Workshop 1: Novel Constructs
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 6 of 7
Yu-Sang Sabrina Yang, Massachusetts Institute of Technology, USA
Targeting Immunomodulators to Lymphocytes Via Amphiphilic Gold Nanocarriers


Monday, March 07 | 2:30PM - 4:30PM
Workshop 1: Novel Constructs
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 7 of 7
Travis Young, California Institute for Biomedical Research, USA
Antibody-based Control of CAR-T Cell Therapy


Monday, March 07 | 4:30PM - 5:00PM
Coffee Available
Room: Macdonald Foyer


Monday, March 07 | 5:00PM - 7:00PM
Antigen-Presenting Cells
Room: Macdonald DEF

Speaker 1 of 5
* Jacques F. Banchereau, The Jackson Laboratory for Genomic Medicine, USA

Monday, March 07 | 5:00PM - 7:00PM
Antigen-Presenting Cells
Room: Macdonald DEF

Speaker 2 of 5
Julie Magarian Blander, Weill Cornell Medicine, Cornell University, USA
Regulation of Antigen Cross-presentation in Dendritic Cells

Monday, March 07 | 5:00PM - 7:00PM
Antigen-Presenting Cells
Room: Macdonald DEF

Speaker 3 of 5
A. Karolina Palucka, The Jackson Laboratory for Genomic Medicine, USA
Dendritic Cells as Cancer Vaccines

Monday, March 07 | 5:00PM - 7:00PM
Antigen-Presenting Cells
Room: Macdonald DEF

Speaker 4 of 5
Matthew F. Krummel, University of California, San Francisco, USA
T Cell-Antigen Presenting Dynamics in the Tumor Microenvironment

Monday, March 07 | 5:00PM - 7:00PM
Antigen-Presenting Cells
Room: Macdonald DEF

Speaker 5 of 5
Brian J. Francica, Tempest Therapeutics, USA
Short Talk: Radio-resistant Stromal Cells Initiate the Innate Response to Cyclic Dinucleotides

Monday, March 07 | 5:00PM - 7:15PM
Engineering Antibody Function
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 1 of 5
* Alison M. Betts, Pfizer, Inc., USA


Monday, March 07 | 5:00PM - 7:15PM
Engineering Antibody Function
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 2 of 5
Margaret E. Ackerman, Dartmouth College, USA
Evolution of Antibodies for Optimized Effector Function Activities


Monday, March 07 | 5:00PM - 7:15PM
Engineering Antibody Function
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 3 of 5
Jeanette H.W. Leusen, University Medical Center Utrecht, Netherlands
IgA as Alternative Therapeutic Antibody: Combination with IgG, Half-Life Extension and More


Monday, March 07 | 5:00PM - 7:15PM
Engineering Antibody Function
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 4 of 5
Sarel J. Fleishman, Weizmann Institute of Science, Israel
De novo Design of Novel Protein Functions


Monday, March 07 | 5:00PM - 7:15PM
Engineering Antibody Function
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 5 of 5
Paul W. H. I. Parren, Leiden University Medical Center, Netherlands
Functional Aspects of Antigen- and Fc-Dependent IgG Hexamer Formation


Monday, March 07 | 7:00PM - 7:00PM
On Own for Dinner


Tuesday, March 08 | 7:00AM - 8:00AM
Breakfast
Room: Frontenac


Tuesday, March 08 | 8:00AM - 11:15AM
Priming Effector T Cells
Room: Macdonald DEF

Speaker 1 of 7
* Sebastian Amigorena, Institut Curie, France

Tuesday, March 08 | 8:00AM - 11:15AM
Priming Effector T Cells
Room: Macdonald DEF

Speaker 2 of 7
Victor Appay, INSERM U1135 - CIMI, France
Impaired Induction of High-Quality Effector CD8+ T-Cells in Old Humans

Tuesday, March 08 | 8:00AM - 11:15AM
Priming Effector T Cells
Room: Macdonald DEF

Speaker 3 of 7
Luca Gattinoni, NCI, National Institutes of Health, USA
Generation of Long-Lived Cancer Antigen-Specific CD8+ T Cell Memory

Tuesday, March 08 | 8:00AM - 11:15AM
Priming Effector T Cells
Room: Macdonald DEF

Speaker 4 of 7
Pamela S. Ohashi, Princess Margaret Cancer Centre, Canada
Novel Subsets Involved in T Cell Anti-Tumor Immunity

Tuesday, March 08 | 8:00AM - 11:15AM
Priming Effector T Cells
Room: Macdonald DEF

Speaker 5 of 7
Ugur Sahin, BioNTech AG, Germany
Exploiting Antiviral Immune Mechanisms for Cancer Immunotherapy

Tuesday, March 08 | 8:00AM - 11:15AM
Priming Effector T Cells
Room: Macdonald DEF

Speaker 6 of 7
Dixon Dorand, Case Western Reserve University, USA
Short Talk: Cyclin Dependent Kinase 5 (CDK5) Controls PD-L1 Expression via Phosphorylation of IRF2BP2 in Murine Medulloblastoma and CDK5 Deficiency Results in CD4+ Dependent T-Cell Rejection

Tuesday, March 08 | 8:00AM - 11:15AM
Priming Effector T Cells
Room: Macdonald DEF

Speaker 7 of 7
Alison Taylor, University of Cambridge, UK
Short Talk: Glycogen Synthase Kinase 3 Inhibition Blocks PD-1 Expression via Increased Tbet Expression for Enhanced CD8+ Cytolytic T-Cell Responses

Tuesday, March 08 | 8:00AM - 11:00AM
B Cell Biology and Antibody Repertoires
This session is from Antibodies as Drugs
Room: Macdonald ABC
How the immune system adapts to infection and other challenges, and how antibody combinations can be used to treat diseases.
Speaker 1 of 6
* David A. Scheinberg, Memorial Sloan Kettering Cancer Center, USA


Tuesday, March 08 | 8:00AM - 11:00AM
B Cell Biology and Antibody Repertoires
This session is from Antibodies as Drugs
Room: Macdonald ABC
How the immune system adapts to infection and other challenges, and how antibody combinations can be used to treat diseases.
Speaker 2 of 6
George Georgiou, University of Texas at Austin, USA
Systematic Characterization and Comparative Analysis of Antibody Repertoires


Tuesday, March 08 | 8:00AM - 11:00AM
B Cell Biology and Antibody Repertoires
This session is from Antibodies as Drugs
Room: Macdonald ABC
How the immune system adapts to infection and other challenges, and how antibody combinations can be used to treat diseases.
Speaker 3 of 6
Pavel Tolar, Francis Crick Institute, UK
EMBO Young Investigator Lecture: Regulation of Antibody Responses by B Cell Mechanical Activity


Tuesday, March 08 | 8:00AM - 11:00AM
B Cell Biology and Antibody Repertoires
This session is from Antibodies as Drugs
Room: Macdonald ABC
How the immune system adapts to infection and other challenges, and how antibody combinations can be used to treat diseases.
Speaker 4 of 6
Laura M. Walker, Adimab LLC, USA
Rapid and Large-Scale Isolation of Potent Neutralizing Antibodies from a Survivor of the 2014 Ebola Virus Outbreak


Tuesday, March 08 | 8:00AM - 11:00AM
B Cell Biology and Antibody Repertoires
This session is from Antibodies as Drugs
Room: Macdonald ABC
How the immune system adapts to infection and other challenges, and how antibody combinations can be used to treat diseases.
Speaker 5 of 6
Paul A. Ramsland, RMIT University, Australia
Short Talk: Unanticipated Global Changes in IgG1 from Mutation of FcRn Binding Site Residues


Tuesday, March 08 | 8:00AM - 11:00AM
B Cell Biology and Antibody Repertoires
This session is from Antibodies as Drugs
Room: Macdonald ABC
How the immune system adapts to infection and other challenges, and how antibody combinations can be used to treat diseases.
Speaker 6 of 6
Sai T. Reddy, ETH Zurich, Switzerland
Short Talk: Correlations of Antibody Response Phenotype to Genotype Revealed by Molecular Amplification Fingerprinting


Tuesday, March 08 | 9:20AM - 9:40AM
Coffee Break
Room: Macdonald Foyer


Tuesday, March 08 | 11:15AM - 1:00PM
Poster Setup
Room: Frontenac


Tuesday, March 08 | 11:15AM - 2:30PM
On Own for Lunch


Tuesday, March 08 | 1:00PM - 10:00PM
Poster Viewing
Room: Frontenac


Tuesday, March 08 | 2:30PM - 4:30PM
Workshop 2: Cell-Based Vaccines
Room: Macdonald DEF

Speaker 1 of 9
* Masaki Terabe, NCI, National Institutes of Health, USA

Tuesday, March 08 | 2:30PM - 4:30PM
Workshop 2: Cell-Based Vaccines
Room: Macdonald DEF

Speaker 2 of 9
* Robert A. Seder, NIAID, National Institutes of Health, USA

Tuesday, March 08 | 2:30PM - 4:30PM
Workshop 2: Cell-Based Vaccines
Room: Macdonald DEF

Speaker 3 of 9
Andres Alloatti, Institut Curie, France
Dissecting Cross-Presentation in Dendritic Cells: Who, How and Why?

Tuesday, March 08 | 2:30PM - 4:30PM
Workshop 2: Cell-Based Vaccines
Room: Macdonald DEF

Speaker 4 of 9
Anja C. Bloom, NCI, National Institutes of Health, USA
INT230-6 Administered Intratumorally Converts Tumor to an Endogenous Vaccine in Mouse Colon Cancer

Tuesday, March 08 | 2:30PM - 4:30PM
Workshop 2: Cell-Based Vaccines
Room: Macdonald DEF

Speaker 5 of 9
Agamemnon Antoniou Epenetos, Imperial College London, UK
Creation of Biological Microparticles from Mesenchymal Stem Cell (MSC) to Deliver Vaccines and other Therapeutics such as Proteins or Nucleic Acids

Tuesday, March 08 | 2:30PM - 4:30PM
Workshop 2: Cell-Based Vaccines
Room: Macdonald DEF

Speaker 6 of 9
Simon Heidegger, Klinikum Rechts der Isar, Technical University Munich, Germany
Activation of the Cytosolic RNA Receptor RIG-I in Tumor and Immune Cells Triggers Efficient Anti-Tumor Immunity and Synergizes with Checkpoint Blockade

Tuesday, March 08 | 2:30PM - 4:30PM
Workshop 2: Cell-Based Vaccines
Room: Macdonald DEF

Speaker 7 of 9
Kavya Rakhra, Massachusetts Institute of Technology, USA
Combination Immunotherapy of an Autochthonous Murine Lung Cancer Model Expressing Human CEA as a Tumor-Associated Self-Antigen

Tuesday, March 08 | 2:30PM - 4:30PM
Workshop 2: Cell-Based Vaccines
Room: Macdonald DEF

Speaker 8 of 9
Yvette van Kooyk, Vrije University Medical Center, Netherlands
Vaccines Facilitating Cross-Presentation for the Induction of Tumor-Immunity Overcoming Tumor Induced Suppression

Tuesday, March 08 | 2:30PM - 4:30PM
Workshop 2: Cell-Based Vaccines
Room: Macdonald DEF

Speaker 9 of 9
Megan C. Wise, Inovio Pharmaceuticals, USA
Various forms of CD40L Encoded as an Immune Plasmid Adjuvant Generate Unique Anti-HPV DNA Vaccine Induced Responses

Tuesday, March 08 | 4:30PM - 5:00PM
Coffee Available
Room: Macdonald Foyer


Tuesday, March 08 | 5:00PM - 7:00PM
Reprogramming T Cell Memory
Room: Macdonald DEF

Speaker 1 of 5
* Victor Appay, INSERM U1135 - CIMI, France

Tuesday, March 08 | 5:00PM - 7:00PM
Reprogramming T Cell Memory
Room: Macdonald DEF

Speaker 2 of 5
Rafi Ahmed, Emory University School of Medicine, USA
Features of Memory CD8+ T Cells in Chronic Infection

Tuesday, March 08 | 5:00PM - 7:00PM
Reprogramming T Cell Memory
Room: Macdonald DEF

Speaker 3 of 5
Nicholas P. Restifo, Lyell, USA
Lineage Relationship of Effector and Memory T Cells

Tuesday, March 08 | 5:00PM - 7:00PM
Reprogramming T Cell Memory
Room: Macdonald DEF

Speaker 4 of 5
Jonathan D. Powell, Johns Hopkins University School of Medicine, USA
Targeting Immunometabolism as a Means of Enhancing Immunotherapy

Tuesday, March 08 | 5:00PM - 7:00PM
Reprogramming T Cell Memory
Room: Macdonald DEF

Speaker 5 of 5
Madhusudhanan Sukumar, NCI, National Institutes of Health, USA
Short Talk: Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for TCR and CAR based Adoptive Immunotherapy of Cancer

Tuesday, March 08 | 5:00PM - 7:15PM
Novel Antibody Constructs
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 1 of 5
* Anna M. Wu, University of California, Los Angeles, USA


Tuesday, March 08 | 5:00PM - 7:15PM
Novel Antibody Constructs
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 2 of 5
David A. Scheinberg, Memorial Sloan Kettering Cancer Center, USA
Drugging Intracellular Targets with Vaccines and Human Therapeutic TCR Mimic Antibodies


Tuesday, March 08 | 5:00PM - 7:15PM
Novel Antibody Constructs
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 3 of 5
Dennis R. Benjamin, Seattle Genetics Inc., USA
Antibody Drug Conjugates for Cancer Therapy


Tuesday, March 08 | 5:00PM - 7:15PM
Novel Antibody Constructs
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 4 of 5
Birgit Schoeberl, Novartis Institutes for BioMedical Research, USA
Multispecific Antibody Therapeutics Derived from Systems Biology and Computational Modeling


Tuesday, March 08 | 5:00PM - 7:15PM
Novel Antibody Constructs
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 5 of 5
John C. Williams, Beckman Research Institute at City of Hope, USA
Functionalization of MAbs Using Mechanical Bonds


Tuesday, March 08 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Frontenac
No registration fees are used to fund alcohol served at this function.

Tuesday, March 08 | 7:30PM - 10:00PM
Poster Session 2
Room: Frontenac


Wednesday, March 09 | 7:00AM - 8:00AM
Breakfast
Room: Frontenac


Wednesday, March 09 | 8:00AM - 11:00AM
Cancer Vaccines
Room: Macdonald DEF

Speaker 1 of 6
* Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands

Wednesday, March 09 | 8:00AM - 11:00AM
Cancer Vaccines
Room: Macdonald DEF

Speaker 2 of 6
Laurence Zitvogel, Institut Gustave Roussy, France
Molecular Mechanisms of Cancer Antigen Presentation at the Tumor Site

Wednesday, March 09 | 8:00AM - 11:00AM
Cancer Vaccines
Room: Macdonald DEF

Speaker 3 of 6
Thomas W. Dubensky, Jr., Tempest Therapeutics, USA
Insights from Listeria monocytogenes for the Development of Vector- and Small Molecule-Based Cancer Immunotherapy Strategies

Wednesday, March 09 | 8:00AM - 11:00AM
Cancer Vaccines
Room: Macdonald DEF

Speaker 4 of 6
Howard L. Kaufman, Massachusetts General Hospital, USA
Advances in Oncolytic Virus Immunotherapy

Wednesday, March 09 | 8:00AM - 11:00AM
Cancer Vaccines
Room: Macdonald DEF

Speaker 5 of 6
Sandra Demaria, Weill Cornell Medical College, USA
In situ Vaccination by Radiation Therapy

Wednesday, March 09 | 8:00AM - 11:00AM
Cancer Vaccines
Room: Macdonald DEF

Speaker 6 of 6
Rupert Kenefeck, Immunocore Ltd., UK
Short Talk: Overcoming Immune Regulation to Kill Cancers: ImmTAC Targeting and Checkpoint Inhibition

Wednesday, March 09 | 8:00AM - 11:00AM
Targeted Delivery for Imaging and Therapy
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 1 of 6
* Alan J. Korman, Vir Biotechnology, Inc., USA


Wednesday, March 09 | 8:00AM - 11:00AM
Targeted Delivery for Imaging and Therapy
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 2 of 6
Anna M. Wu, University of California, Los Angeles, USA
Detecting Tumor and Immune Cell Responses to Therapy Using ImmunoPET


Wednesday, March 09 | 8:00AM - 11:00AM
Targeted Delivery for Imaging and Therapy
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 3 of 6
Katherine A. Vallis, University of Oxford, UK
Antibody-Based Radiotherapy and Radiodetection of Cancer


Wednesday, March 09 | 8:00AM - 11:00AM
Targeted Delivery for Imaging and Therapy
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 4 of 6
Colin E. Correnti, Fred Hutchinson Cancer Research Center, USA
Tumor Paint and Penetrating Peptide Drug Conjugates


Wednesday, March 09 | 8:00AM - 11:00AM
Targeted Delivery for Imaging and Therapy
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 5 of 6
Jacob Petersburg, University of Minnesota, USA
Short Talk: Utilizing Prosthetic Antigen Receptors (PARs) for Anti-EpCAM Cell-directed Immunotherapy


Wednesday, March 09 | 8:00AM - 11:00AM
Targeted Delivery for Imaging and Therapy
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 6 of 6
David T. Rodgers, Calibr, USA
Short Talk: Antibody Based Switches Control the Activation and Targeting of CAR T Cells for B Cell Malignancies


Wednesday, March 09 | 9:20AM - 9:40AM
Coffee Break
Room: Macdonald Foyer


Wednesday, March 09 | 11:00AM - 1:00PM
Poster Setup
Room: Frontenac


Wednesday, March 09 | 11:00AM - 5:00PM
On Own for Lunch


Wednesday, March 09 | 1:00PM - 10:00PM
Poster Viewing
Room: Frontenac


Wednesday, March 09 | 2:30PM - 4:30PM
Workshop 2: Novel Designs and Therapeutics
This session is from Antibodies as Drugs
Room: Macdonald Ballroom

Speaker 1 of 8
* Margaret E. Ackerman, Dartmouth College, USA


Wednesday, March 09 | 2:30PM - 4:30PM
Workshop 2: Novel Designs and Therapeutics
This session is from Antibodies as Drugs
Room: Macdonald Ballroom

Speaker 2 of 8
Hamid Bassiri, Children's Hospital of Philadelphia, USA
Novel Invariant Natural Killer T Cell-Based Immunotherapies for Cancer


Wednesday, March 09 | 2:30PM - 4:30PM
Workshop 2: Novel Designs and Therapeutics
This session is from Antibodies as Drugs
Room: Macdonald Ballroom

Speaker 3 of 8
Hanke Matlung, Sanquin Research and Landsteiner Laboratory, Netherlands
Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis


Wednesday, March 09 | 2:30PM - 4:30PM
Workshop 2: Novel Designs and Therapeutics
This session is from Antibodies as Drugs
Room: Macdonald Ballroom

Speaker 4 of 8
Sheena N. Smith, University of Zurich, Switzerland
Targeted Adenoviral Delivery of Protein-Based Therapeutics to the Tumor Microenvironment


Wednesday, March 09 | 2:30PM - 4:30PM
Workshop 2: Novel Designs and Therapeutics
This session is from Antibodies as Drugs
Room: Macdonald Ballroom

Speaker 5 of 8
Michael W. Munks, Oregon Health & Science University, USA
Major Histocompatibility Class I - Antibody Fusion Proteins (pMHCI-IgGs) that Link B16 Melanoma Cells to Cytomegalovirus-Specific CD8 T Cells Control B16 Melanoma in vivo


Wednesday, March 09 | 2:30PM - 4:30PM
Workshop 2: Novel Designs and Therapeutics
This session is from Antibodies as Drugs
Room: Macdonald Ballroom

Speaker 6 of 8
Huafeng Xu, D.E. Shaw Research LLC, USA
Divergent Sequences Stabilize Similar Antigen-Binding Conformations in the Affinity Maturation of a Broadly Neutralizing Influenza Antibody Lineage


Wednesday, March 09 | 2:30PM - 4:30PM
Workshop 2: Novel Designs and Therapeutics
This session is from Antibodies as Drugs
Room: Macdonald Ballroom

Speaker 7 of 8
David P. Humphreys, UCB Pharma, UK
Statistical Design for Effector Function Engineering of Hexameric Fc Domains


Wednesday, March 09 | 2:30PM - 4:30PM
Workshop 2: Novel Designs and Therapeutics
This session is from Antibodies as Drugs
Room: Macdonald Ballroom

Speaker 8 of 8
Andre BH Choo, Bioprocessing Technology Institute, Singapore
Glycan: A Sweet Opportunity for Antibody Discovery


Wednesday, March 09 | 4:30PM - 5:00PM
Coffee Available
Room: Macdonald Foyer


Wednesday, March 09 | 5:00PM - 7:00PM
Antibodies for Checkpoint Blockade (Joint)
Room: Macdonald Ballroom

Speaker 1 of 4
* Madhav V. Dhodapkar, Yale School of Medicine, USA

Wednesday, March 09 | 5:00PM - 7:00PM
Antibodies for Checkpoint Blockade (Joint)
Room: Macdonald Ballroom

Speaker 2 of 4
Alan J. Korman, Vir Biotechnology, Inc., USA
Antitumor Activity of Immunomodulatory Antibodies

Wednesday, March 09 | 5:00PM - 7:00PM
Antibodies for Checkpoint Blockade (Joint)
Room: Macdonald Ballroom

Speaker 3 of 4
Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
PD-1 Blockade in Cancer Therapy: Mechanism-Based Biomarkers and New Frontiers

Wednesday, March 09 | 5:00PM - 7:00PM
Antibodies for Checkpoint Blockade (Joint)
Room: Macdonald Ballroom

Speaker 4 of 4
John J. Miles, QIMR Berghofer Medical Research Institute, Australia
CD96/TIGIT/DNAM Pathway and Tumor Rejection

Wednesday, March 09 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Frontenac
No registration fees are used to fund alcohol served at this function.

Wednesday, March 09 | 7:30PM - 10:00PM
Poster Session 3
Room: Frontenac


Thursday, March 10 | 7:00AM - 8:00AM
Breakfast
Room: Frontenac


Thursday, March 10 | 8:00AM - 11:15AM
Antibodies as Co-Factors (Joint)
Room: Macdonald Ballroom

Speaker 1 of 7
* Laurence Zitvogel, Institut Gustave Roussy, France

Thursday, March 10 | 8:00AM - 11:15AM
Antibodies as Co-Factors (Joint)
Room: Macdonald Ballroom

Speaker 2 of 7
Madhav V. Dhodapkar, Yale School of Medicine, USA
Harnessing Host Response to Premalignancy in Prevention of Cancer

Thursday, March 10 | 8:00AM - 11:15AM
Antibodies as Co-Factors (Joint)
Room: Macdonald Ballroom

Speaker 3 of 7
Carl G. Figdor, Radboud University Medical Center, Netherlands
Dendritic Cell Based Cancer Immunotherapy

Thursday, March 10 | 8:00AM - 11:15AM
Antibodies as Co-Factors (Joint)
Room: Macdonald Ballroom

Speaker 4 of 7
Ira Mellman, Genentech, Inc., USA
The Mechanistic Basis of Cancer Immunotherapy

Thursday, March 10 | 8:00AM - 11:15AM
Antibodies as Co-Factors (Joint)
Room: Macdonald Ballroom

Speaker 5 of 7
Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, USA
Modulation of Innate Immunity in Cancer

Thursday, March 10 | 8:00AM - 11:15AM
Antibodies as Co-Factors (Joint)
Room: Macdonald Ballroom

Speaker 6 of 7
Kelly D. Moynihan, Third Rock Ventures, USA
Short Talk: Eradication of Large Established Tumors by Combination Immunotherapy Engaging Innate and Adaptive Immunity

Thursday, March 10 | 8:00AM - 11:15AM
Antibodies as Co-Factors (Joint)
Room: Macdonald Ballroom

Speaker 7 of 7
Rony Dahan, Rockefeller University, USA
Short Talk: Improved Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Abs by Selective FcgammaR-Engagement

Thursday, March 10 | 9:20AM - 9:40AM
Coffee Break
Room: Macdonald Foyer


Thursday, March 10 | 11:15AM - 2:30PM
On Own for Lunch


Thursday, March 10 | 2:30PM - 4:30PM
Workshop 3: Peptides as Vaccines
Room: Macdonald DEF

Speaker 1 of 9
* Robert D. Schreiber, Washington University School of Medicine, USA

Thursday, March 10 | 2:30PM - 4:30PM
Workshop 3: Peptides as Vaccines
Room: Macdonald DEF

Speaker 2 of 9
Anne-Mette Bjerregaard, Technical University of Denmark, Denmark
MuPeXI: A Tool for Prediction of Neo-Epitopes from Tumor Sequencing Data

Thursday, March 10 | 2:30PM - 4:30PM
Workshop 3: Peptides as Vaccines
Room: Macdonald DEF

Speaker 3 of 9
Gustav Gaudernack, Ultimovacs AS/Norwegian Radium Hospital, Norway
UV1 – A Second-Generation, Peptide-Based, Therapeutic Cancer Vaccine (TCV) Targeting the Reverse Transcriptase Subunit of Human Telomerase (hTERT

Thursday, March 10 | 2:30PM - 4:30PM
Workshop 3: Peptides as Vaccines
Room: Macdonald DEF

Speaker 4 of 9
Matthew M. Gubin, Washington University in St. Louis, USA
Tumor-Specific Mutant Antigens in Cancer Immunotherapy

Thursday, March 10 | 2:30PM - 4:30PM
Workshop 3: Peptides as Vaccines
Room: Macdonald DEF

Speaker 5 of 9
Bruno Laugel, Institut De Recherche Servier, France
Safety Assessment of DNA Methyl Transferase Inhibitors in Combination with NY-ESO T-cell Therapy.

Thursday, March 10 | 2:30PM - 4:30PM
Workshop 3: Peptides as Vaccines
Room: Macdonald DEF

Speaker 6 of 9
Aizea Morales Kastresana, NCI, National Institutes of Health, USA
Optimization of Extracellular Vesicle Labels for NanoFACS

Thursday, March 10 | 2:30PM - 4:30PM
Workshop 3: Peptides as Vaccines
Room: Macdonald DEF

Speaker 7 of 9
Hideho Okada, University of California, San Francisco, USA
Novel and Shared Neoantigen for Glioma T Cell Therapy Derived from Histone 3 Variant H3.3 K27M Mutation

Thursday, March 10 | 2:30PM - 4:30PM
Workshop 3: Peptides as Vaccines
Room: Macdonald DEF

Speaker 8 of 9
Jeffrey Ward, Washington University School of Medicine, USA
Tumor Mutant Antigen-Specific CD8+ T-cells Require CD4+ T-cell Help to Induce Tumor Regression

Thursday, March 10 | 2:30PM - 4:30PM
Workshop 3: Peptides as Vaccines
Room: Macdonald DEF

Speaker 9 of 9
Klaus Früh, Oregon Health & Science University, USA
CMV-induced MHC-II and MHC-E-Restricted CD8+ T Cells: A Role in Cancer Immunotherapy

Thursday, March 10 | 4:30PM - 5:00PM
Coffee Available
Room: Macdonald Foyer


Thursday, March 10 | 5:00PM - 6:45PM
Linking Cancer Genetics and Genomics with Immunity
Room: Macdonald DEF

Speaker 1 of 4
* Hyam I. Levitsky, Century Therapeutics, USA

Thursday, March 10 | 5:00PM - 6:45PM
Linking Cancer Genetics and Genomics with Immunity
Room: Macdonald DEF

Speaker 2 of 4
Jacques F. Banchereau, The Jackson Laboratory for Genomic Medicine, USA
Genomics of Human Immune Response

Thursday, March 10 | 5:00PM - 6:45PM
Linking Cancer Genetics and Genomics with Immunity
Room: Macdonald DEF

Speaker 3 of 4
Robert D. Schreiber, Washington University School of Medicine, USA
Cancer-Specific Mutations as Tumor Rejection Antigens

Thursday, March 10 | 5:00PM - 6:45PM
Linking Cancer Genetics and Genomics with Immunity
Room: Macdonald DEF

Speaker 4 of 4
Catherine J. Wu, Dana-Farber Cancer Institute, USA
Targeting Tumor Neoantigens: Developing Personalized Cancer Vaccines

Thursday, March 10 | 5:00PM - 6:45PM
Antibodies for the Treatment of Infectious Diseases
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 1 of 2
Leo James, MRC Laboratory of Molecular Biology, UK
Intracellular Antibody Immunity and the Cytosolic Fc Receptor TRIM21


Thursday, March 10 | 5:00PM - 6:45PM
Antibodies for the Treatment of Infectious Diseases
This session is from Antibodies as Drugs
Room: Macdonald ABC

Speaker 2 of 2
Carole A. Bewley, National Institutes of Health, USA
Antibody-like Properties and Functions of Antiviral Carbohydrate Binding Proteins


Thursday, March 10 | 6:45PM - 7:00PM
The Human Vaccines Project: A Roadmap to Effective Cancer Va
ccine and Immunotherapeutic Development

Room: Macdonald DEF

Speaker 1 of 2
* A. Karolina Palucka, The Jackson Laboratory for Genomic Medicine, USA

Thursday, March 10 | 6:45PM - 7:00PM
The Human Vaccines Project: A Roadmap to Effective Cancer Va
ccine and Immunotherapeutic Development

Room: Macdonald DEF

Speaker 2 of 2
Theodore Schenkelberg, Human Vaccines Project, USA

Thursday, March 10 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
This session is from Antibodies as Drugs
Room: Macdonald ABC


Thursday, March 10 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Frontenac
No registration fees are used to fund alcohol served at this function.

Thursday, March 10 | 8:00PM - 11:00PM
Entertainment
Room: Frontenac
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, March 10 | 8:00PM - 11:00PM
Cash Bar
Room: Frontenac


Friday, March 11 | 10:25AM - 10:25AM
Departure


*Session Chair.